Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $7.54 |
|---|---|
| 52-week range | $5.42 - $14.97 |
| 50-day moving average | $9.01 |
| 200-day moving average | $10.53 |
| Wall St. target price | $28.33 |
| PE ratio | 14.85 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.50 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.54 from 2023-03-31
| 1 week (2023-03-22) | 3.15% |
|---|---|
| 1 month (2023-02-28) | -10.24% |
| 3 months (2022-12-29) | -24.98% |
| 6 months (2022-09-29) | -23.45% |
| 1 year (2022-04-01) | -25.57% |
|---|---|
| 2 years (2021-04-01) | -75.45% |
| 3 years (2020-03-28) | N/A |
| 5 years (2018-03-28) | N/A |
Valuing Abcellera Biologics Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcellera Biologics Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
To put Abcellera Biologics Inc's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $485.4 million |
|---|---|
| Operating margin TTM | 44.6% |
| Gross profit TTM | $311.1 million |
| Return on assets TTM | 9.47% |
| Return on equity TTM | 14.03% |
| Profit margin | 32.66% |
| Book value | $4.30 |
| Market capitalisation | $2.2 billion |
TTM: trailing 12 months
We're not expecting Abcellera Biologics Inc to pay a dividend over the next 12 months.
Over the last 12 months, Abcellera Biologics Inc's shares have ranged in value from as little as $5.42 up to $14.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abcellera Biologics Inc's is -0.0916. This would suggest that Abcellera Biologics Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Abcellera Biologics Inc has bucked the trend.
To put Abcellera Biologics Inc's beta into context you can compare it against those of similar companies.
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. .
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.